Irish jobs at risk in AstraZeneca
UP to 90 staff at the Irish arm of UK drug maker AstraZeneca are bracing for job cuts after the company said it plans to axe 2,300 global positions.
The company said that the cuts would primarily be among its sales, marketing and administrative staff. The bulk of the people it employs in Ireland are engaged in those roles.
But a spokeswoman for the company told the Irish Independent that she couldn't precisely say how many roles in Ireland could be impacted.
"They're likely to be as impacted as anybody else," she said.
AstraZeneca Pharmaceuticals (Ireland) employed 88 people at the end of 2011, down from 94 at the end of the previous year. In 2011, 62 of them were involved in sales and marketing and 12 in administration.
The Irish arm made a near €3m operating profit in 2011, down from €4.5m in 2010. Turnover fell to €19.6m from €23.5m.
AstraZeneca plans to axe 2,300 staff and narrow its drug research focus in a bid to return to earnings growth as patents on its best-selling medicines expire. The company, the UK's second-biggest drugmaker, is trying to recover from setbacks in developing treatments for rheumatoid arthritis, cancer and depression.